The Diabetes Atherosclerosis Intervention Study (DAIS) was a multicentre, double-blind, randomised, placebo controlled, angiographic trial of the effects of fenofibrate on lipoprotein abnormalities in people with type 2 diabetes. Fenofibrate improved the lipid profile and retarded the progression of coronary artery disease. DAIS and its implications are considered within the context of other major lipid studies.
Steiner G.Atherosclerosis, the major complication of diabetes. Adv Exp Med Biol1985;189:277-97.
2.
Anonymous.The Lipid Research Clinics Coronary Primary Prevention Trial results. I. Reduction in incidence of coronary heart diseaseJAMA1984; 251:351-64.
3.
Anonymous.The Lipid Research Clinics Coronary Primary Prevention Trial results. II. The relationship of reduction in incidence of coronary heart disease to cholesterol loweringJAMA1984;251:365-74.
4.
Steiner G.The Diabetes Atherosclerosis Intervention Study (DAIS): a study conducted in cooperation with the World Health Organisation. Diabetologia1996;39:1655-61.
5.
Diabetes Atherosclerosis InterventionStudy Investigators.Effect of fenofibrate on progression of coronary artery disease in type 2 diabetes: the Diabetes Atherosclerosis Intervention Study, a randomised study. Lancet2001;357:905-10.
6.
McGuiness C. , Seccombe DW, Frohlich JJ et al. Laboratory standardisation in a large international clinical trial: the DAIS experience. Clin Biochem2000;33:15-24.
Vakkilainen J., Steiner G., Ansquer JC et al. DAIS Group. Relationships between low density lipoprotein particle size, plasma lipoproteins and progression of coronary artery disease. The Diabetes Atherosclerosis Intervention Study (DAIS) Circulation2003;107:1733-7.
9.
Frick MH, Elo O., Haapa K. et al. Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia: safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med1987;317:1237-45.
10.
Koskinen P. , Manttari M., Manninen V., Huttunen JK, Heinonen OP, Frick MHCoronary heart disease incidence in NIDDM patients in the Helsinki Heart Study. Diabetes Care1992;15:820-5.
11.
Downs JR, Clearfield M., Weis S. et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention. JAMA1998;279:1615-22.
12.
Scandinavian Simvastatin SurvivalStudy Group.Randomised trial of cholesterol lowering in 4,444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet1994;344:1383-9.
13.
Pyorala K., Pedersen TR, Kjekshus J., Faergeman O., Olsson AG, Thorgeirsson G.Cholesterol lowering with simvastatin improves the prognosis of diabetic patients with coronary heart disease. Diabetes Care1997;20:614-20.
14.
Goldberg RB , Mellies MJ, Sacks FM et al. Cardiovascular events and their reduction with pravastatin in diabetic and glucose-intolerant myocardial infarction survivors with average cholesterol levels: subgroup analyses in the Cholesterol and Recurrent Events (CARE) Trial. Circulation1998;98: 2513-19.
15.
The LIPID Study Group.Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels . N Engl J Med1998;76:474-9.
16.
Heart Protection StudyCollaborative Group.MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet2002;360:7-22.
17.
Elkeles RS, Diamond JR, Poulter C. et al. the SENDCAP Study Group.Cardiovascular outcomes in type 2 diabetes: A double-blind placebo-controlled study of bezafibrate: the St. Mary's, Ealing, Northwick Park Diabetes Cardiovascular Disease Prevention (SENDCAP) StudyDiabetes Care1998;21:641-8.
18.
Rubins HB, Robins SJ, Collins D. et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol: Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N Engl J Med1999;341:410-18.
